The Effect of Structured Transition Care Model Applied to Adolescents With Congenital Heart Disease
Launched by ANKARA YILDIRIM BEYAZIT UNIVERSITY · May 23, 2024
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help teenagers with congenital heart disease, which means they were born with heart problems. The focus is on making sure these young people are ready to move from pediatric care (care for children) to adult care, which can be a big change. Researchers want to see if a special program called the developmental transition care model can improve how well these teens feel prepared for adult health care, how they manage their own health, and their satisfaction with the care they receive.
To participate in this study, teens need to be between 16 and 20 years old, have a diagnosis of congenital heart disease, and have been receiving care for at least a year. They should also be able to communicate in Turkish and not have any mental health issues that would make it hard to participate. Participants can expect to receive support and education to help them feel more comfortable and capable as they transition to adult care. This study aims to help improve the overall experience and health outcomes for these young patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Voluntarily agree to participate in the research
- • To be between the ages of 16-20,
- • Having a diagnosis of congenital heart disease,
- • Being followed up with a diagnosis of congenital heart disease for at least one year in the polyclinics where the study was conducted,
- • To be able to communicate in Turkish,
- • Not having any mental deficiency that may prevent communication
- Exclusion Criteria:
- • Refusing to participate in the research,
- • Not being able to communicate in Turkish,
- • Not showing up regularly for follow-ups,
- • Having any mental disability that may prevent communication
About Ankara Yildirim Beyazıt University
Ankara Yıldırım Beyazıt University is a leading academic institution in Turkey, renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, the university leverages its expertise in healthcare and innovative research methodologies to conduct ethical and scientifically rigorous clinical studies. By fostering collaboration among multidisciplinary teams, Ankara Yıldırım Beyazıt University aims to contribute to the development of novel therapies and enhance patient care, while adhering to the highest standards of regulatory compliance and patient safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, Ankara Yenimahalle, Turkey
Patients applied
Trial Officials
Tutku KIRÇI TEMİZ, PhD s.
Principal Investigator
Ankara Yildirim Beyazıt University
Evrim KIZILER, Asst.Prof.
Study Director
Ankara Yildirim Beyazıt University
Utku ARMAN ÖRÜN, Prof.Dr.
Study Director
Republic of Turkey Ministry of Health Ankara Etlik City Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported